{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:14:20Z","timestamp":1715213660709},"reference-count":21,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.3960\/jslrt.20025","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T22:17:30Z","timestamp":1631225850000},"page":"120-125","source":"Crossref","is-referenced-by-count":1,"title":["Increased MYC expression without MYC gene translocation in patients                    with the diffuse large B-cell-lymphoma subtype of iatrogenic                    immunodeficiency-associated lymphoproliferative disorders"],"prefix":"10.3960","volume":"61","author":[{"given":"Nobuyuki","family":"Kabasawa","sequence":"first","affiliation":[{"name":"Department of Pathology, Showa University                            School of Medicine, Tokyo, Japan,"},{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Shiozawa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Showa University                            School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So","family":"Murai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Showa University                            School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Homma","sequence":"additional","affiliation":[{"name":"Department of Pathology, Showa University                            School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Uesugi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoharu","family":"Matsui","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Nakata","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Shimada","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Baba","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Watanuki","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Uto","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norimichi","family":"Hattori","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Sakai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University Fujigaoka Hospital, Kanagawa,                            Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Harada","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University Fujigaoka Hospital, Kanagawa,                            Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Nakamaki","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of                            Medicine, Showa University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Takimoto","sequence":"additional","affiliation":[{"name":"Department of Pathology, Showa University                            School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiko","family":"Yamochi-Onizuka","sequence":"additional","affiliation":[{"name":"Department of Pathology, Showa University                            School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Swerdlow SH, Webber SA, Chadobum A, Ferry                    JA. Post-transplant lymphoproliferative disorders. In : Swerdlow SH, Campo E,                    Harris NL, <i>et al<\/i>. (eds) : WHO Classification of Tumours of                    Haematopoietic and Lymphoid Tissues, Revised 4th ed, Lyon, International Agency                    for Research on Cancer. 2017; pp. 453-462."},{"key":"2","unstructured":"2 Gaulard P, Swerdlow SH, Harris NL, Sundstr\u00f6m                    C, Jaffe ES. Other iatrogenic immunodeficiency associated lymphoproliferative                    disorders. In : Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds) :                    WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised                    4th ed, Lyon, International Agency for Research on Cancer. 2017; pp.                    462-464."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Marques-Piubelli                            ML,                                Salas                            YI,                                Pachas                            C                    <i>et al.<\/i> Epstein\u2013Barr virus-associated B-cell lymphoproliferative                    disorders and lymphomas: a review. Pathology. 2020; 52: 40-52.","DOI":"10.1016\/j.pathol.2019.09.006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Ru                            Y,                                Chen                            J,                                Wu                            D. Epstein-Barr                    virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic                    stem cell transplantation. Eur J Haematol. 2018; 101: 283-290.","DOI":"10.1111\/ejh.13131"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Al-Mansour                            Z,                                Nelson                            BP,                                Evens                            AM.                    Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and                    current treatment strategies. Curr Hematol Malig Rep. 2013; 8:                    173-183.","DOI":"10.1007\/s11899-013-0162-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Spevak                            CC,                                Park                            CY. Novel                    mechanism regulates c-Myc expression in diffuse large B-cell lymphoma. J Natl                    Cancer Inst. 2020; 112: 7-9.","DOI":"10.1093\/jnci\/djz104"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Chen                            H,                                Liu                            H,                                Qing                            G. Targeting                    oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther.                    2018; 3: 5.","DOI":"10.1038\/s41392-018-0008-7"},{"key":"8","unstructured":"8 Leoncini L, Campo E, Stein H, et al. Burkit                    lymphoma. In : Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds) :                    WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised                    4th ed, Lyon, International Agency for Research on Cancer. 2017; pp.                    330-334."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Hans                            CP,                                Weisenburger                            DD,                                Greiner                            TC                    <i>et al.<\/i> Confirmation of the molecular classification of diffuse                    large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood.                    2004; 103: 275-282.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Abbas                            F, El                                Kossi                            M,                                Shaheen                            IS,                                Sharma                            A,                                Halawa                            A.                    Post-transplantation lymphoproliferative disorders: current concepts and future                    therapeutic approaches. World J Transplant. 2020; 10: 29-46.","DOI":"10.5500\/wjt.v10.i2.29"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Alizadeh                            AA,                                Eisen                            MB,                                Davis                            RE                    <i>et al.<\/i> Distinct types of diffuse large B-cell lymphoma                    identified by gene expression profiling. Nature. 2000; 403:                    503-511.","DOI":"10.1038\/35000501"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Choi                            WWL,                                Weisenburger                            DD,                                Greiner                            TC                    <i>et al.<\/i> A new immunostain algorithm classifies diffuse large                    B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res.                    2009; 15: 5494-5502.","DOI":"10.1158\/1078-0432.CCR-09-0113"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Seki                            R,                                Ohshima                            K,                                Fujisaki                            T                    <i>et al.<\/i> Prognostic impact of immunohistochemical biomarkers in                    diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2009; 100:                    1842-1847.","DOI":"10.1111\/j.1349-7006.2009.01268.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 van                                der Weyden                            CA,                                Pileri                            SA,                                Feldman                            AL,                                Whisstock                            J,                                Prince                            HM.                    Understanding CD30 biology and therapeutic targeting: a historical perspective                    providing insight into future directions. Blood Cancer J. 2017; 7:                        e603.","DOI":"10.1038\/bcj.2017.85"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Jacobsen                            ED,                                Sharman                            JP,                                Oki                            Y                    <i>et al.<\/i> Brentuximab vedotin demonstrates objective responses in                    a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression.                    Blood. 2015; 125: 1394-1402.","DOI":"10.1182\/blood-2014-09-598763"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Crombie                            JL,                                LaCasce                            AS. Epstein Barr                    virus associated B-cell lymphomas and iatrogenic lymphoproliferative disorders.                    Front Oncol. 2019; 9: 109.","DOI":"10.3389\/fonc.2019.00109"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Djokic                            M, Le                                Beau                            MM,                                Swinnen                            LJ                    <i>et al.<\/i> Post-transplant lymphoproliferative disorder subtypes                    correlate with different recurring chromosomal abnormalities. Genes Chromosomes                    Cancer. 2006; 45: 313-318.","DOI":"10.1002\/gcc.20287"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Carreras                            J, Yukie                                Kikuti                            Y,                                Miyaoka                            M                    <i>et al.<\/i> Genomic profile and pathologic features of diffuse large                    B-cell lymphoma subtype of methotrexate-associated lymphoproliferative disorder                    in rheumatoid arthritis patients. Am J Surg Pathol. 2018; 42:                    936-950.","DOI":"10.1097\/PAS.0000000000001071"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kramer                            MHH,                                Hermans                            J,                                Wijburg                            E                    <i>et al.<\/i> Clinical relevance of BCL2, BCL6, and MYC rearrangements                    in diffuse large B-cell lymphoma. Blood. 1998; 92: 3152-3162.","DOI":"10.1182\/blood.V92.9.3152.421a07_3152_3162"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Xu-Monette                            ZY,                                Dabaja                            BS,                                Wang                            X                    <i>et al.<\/i> Clinical features, tumor biology, and prognosis                    associated with MYC rearrangement and Myc overexpression in diffuse large B-cell                    lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2015; 28:                    1555-1573.","DOI":"10.1038\/modpathol.2015.118"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Meyer                            N,                                Penn                            LZ. Reflecting                    on 25 years with MYC. Nat Rev Cancer. 2008; 8: 976-990.","DOI":"10.1038\/nrc2231"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/3\/61_20025\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T05:25:35Z","timestamp":1715145935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/3\/61_20025\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.20025","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"20025"}}